Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models

Ítems similars

• Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma
  per: Annamaria Brioli, et al.
  Publicat: (2014-11-01)
• Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents
  per: Paola Tacchetti, et al.
  Publicat: (2017-03-01)
• Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma
  per: Flavia Bigi, et al.
  Publicat: (2024-04-01)
• Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models
  per: Enrica Borsi, et al.
  Publicat: (2018-12-01)
• Front-line treatment of multiple myeloma
  per: Michele Cavo, et al.
  Publicat: (2019-06-01)